A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

1997

Supportive Care in Cancer , Volume 5 - Issue 1 p. 22- 30

Additional Metadata
Keywords	5-HT3 receptor antagonist, Antiemetic, Cisplatin, Dolasetron, Metoclopramide
Persistent URL	doi.org/10.1007/s005200050036, hdl.handle.net/1765/61692
Journal	Supportive Care in Cancer
Organisation	Department of Medical Oncology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Chevallier, P., Cappelaere, P., Splinter, T., Fabbro, M., Wendling, J., Cals, L., Catimel, G., Giovannini, M., Khayat, D., Bastit, P.& Claverie, N. (1997). A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Supportive Care in Cancer, 5(1), 22–30.https://doi.org/10.1007/s005200050036

Publication